Joel Greenblatt Atea Pharmaceuticals, Inc. Transaction History

Gotham Asset Management, LLC

  • $9.41 Billion
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
SELL
$5.49 - $8.79 $58,314 - $93,367
-10,622 Reduced 48.17%
11,431 $65,000
Q2 2022

Aug 15, 2022
SELL
$5.33 - $8.18 $49,041 - $75,264
-9,201 Reduced 29.44%
22,053 $157,000
Q1 2022

May 16, 2022
BUY
$5.5 - $9.19 $11,385 - $19,023
2,070 Added 7.09%
31,254 $226,000
Q4 2021

Feb 14, 2022
SELL
$7.67 - $44.59 $114,367 - $664,881
-14,911 Reduced 33.82%
29,184 $261,000
Q3 2021

Nov 15, 2021
BUY
$21.33 - $35.06 $463,500 - $761,853
21,730 Added 97.16%
44,095 $1.55 Million
Q2 2021

Aug 16, 2021
BUY
$19.22 - $59.08 $429,855 - $1.32 Million
22,365 New
22,365 $480,000

Others Institutions Holding AVIR

# of Institutions
112
Shares Held
52.4M
Call Options Held
900
Put Options Held
126K
View Full List

About Atea Pharmaceuticals, Inc.

AVIR Quotes by TradingView
  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $270M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track Joel Greenblatt's Portfolio

Track Joel Greenblatt Portfolio

Follow Joel Greenblatt (Gotham Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email